Výsledky vyhledávání - "Roopa Trivedi"

Akademický článek

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease

Autor: Omar Usmani, Nicolas Roche, Ezanul Wahab, Samuel Israel, Martin Jenkins, Roopa Trivedi, Paul Dorinsky, Magnus Aurivillius

Publikováno v: Respiratory Research, Vol 22, Iss 1, Pp 1-12 (2021)

Abstract Background Triple therapy with inhaled corticosteroids/long-acting muscarinic antagonists/long-acting β2-agonists (ICS/LAMA/LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) with continued symptoms or exace

Externí odkaz: https://doaj.org/article/4ace7cceae114f6da29e506a697a764a

Zobrazit plný text záznamu

Akademický článek

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids

Autor: Maarten van den Berge, Jan De Backer, Cedric Van Holsbeke, Wilfried De Backer, Roopa Trivedi, Martin Jenkins, Paul Dorinsky, Magnus Aurivillius

Publikováno v: Respiratory Research, Vol 22, Iss 1, Pp 1-12 (2021)

Abstract Background For patients with chronic obstructive pulmonary disease (COPD), greater improvements in lung function have been demonstrated for triple versus dual inhaled therapies in traditional spirometry studies. This study was the first to u

Externí odkaz: https://doaj.org/article/bb966b39b5f147d8945f3487af082db9

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial

Autor: Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin Jenkins, Patrick Darken, Magnus Aurivillius, Paul Dorinsky

Publikováno v: Therapeutic Advances in Respiratory Disease, Vol 15 (2021)

Background: In the phase III, 52-week ETHOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled corticosteroid dose level

Externí odkaz: https://doaj.org/article/a2fdc680a15e4f4e899bdc53ab8c9965

Zobrazit plný text záznamu

Autor: Martin Jenkins, Wilfried De Backer, Maarten van den Berge, Roopa Trivedi, Magnus Aurivillius, Jan De Backer, Cedric Van Holsbeke, Paul Dorinsky

Publikováno v: Respiratory Research, Vol 22, Iss 1, Pp 1-12 (2021)
Respiratory Research
Respiratory Research, 22(1):191. BioMed Central Ltd.
Respiratory research

Background For patients with chronic obstructive pulmonary disease (COPD), greater improvements in lung function have been demonstrated for triple versus dual inhaled therapies in traditional spirometry studies. This study was the first to use functi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d932f697b640055e1d53e662473be3
https://doaj.org/article/bb966b39b5f147d8945f3487af082db9

Zobrazit plný text záznamu

Plný text ve formátu HTML

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Autor: Gary T. Ferguson, Kimberly Rossman, Dave Singh, Roopa Trivedi, Earl St Rose, Shaila Ballal, Paul Dorinsky, Fernando J. Martinez, Magnus Aurivillius, Patrick Darken, Colin Reisner, Klaus F. Rabe, Jadwiga A. Wedzicha, Chen Wang

Publikováno v: American Journal of Respiratory and Critical Care Medicine

Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a1058cbdb73d18dbf60fe345e32e86a
http://europepmc.org/articles/PMC7924571

Zobrazit plný text záznamu

Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults

Autor: Kiernan DeAngelis, Paul Dorinsky, Michael Gillen, Paolo DePetrillo, Patrick Darken, Roopa Trivedi

Publikováno v: Clinical Therapeutics. 42:634-648

Purpose The triple combination therapy budesonide/glycopyrrolate/formoterol fumarate in a metered dose inhaler (BGF MDI), formulated by using innovative co-suspension delivery technology, is a new inhaled corticosteroid/long-acting muscarinic antagon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c51b356d8383148738d0126e2d7cff14
https://doi.org/10.1016/j.clinthera.2020.02.012

Zobrazit plný text záznamu

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease

Autor: Paul Dorinsky, Roopa Trivedi, Magnus Aurivillius, Ezanul Abd Wahab, Omar S. Usmani, Samuel Israel, Martin Jenkins, Nicolas Roche

Publikováno v: Respiratory Research, Vol 22, Iss 1, Pp 1-12 (2021)
Respiratory Research

Background Triple therapy with inhaled corticosteroids/long-acting muscarinic antagonists/long-acting β2-agonists (ICS/LAMA/LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) with continued symptoms or exacerbations,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d74e7138efc087034da8ae31130cc0b
http://hdl.handle.net/10044/1/93116

Zobrazit plný text záznamu

S22 Rate of severe COPD exacerbations with Budesonide/Glycopyrronium/Formoterol fumarate dihydrate metered dose inhaler (BGF MDI) versus dual therapies: a post-hoc subgroup analysis of the ETHOS trial

Autor: Gary T. Ferguson, Roopa Trivedi, Dave Singh, Klaus F. Rabe, Paul Dorinsky, Patrick Darken, Magnus Aurivillius, Martin Jenkins, Fernando J. Martinez

Publikováno v: What’s new in COPD?.

Introduction and Objectives The management of chronic obstructive pulmonary disease (COPD) exacerbations varies by region; in most countries, patients are hospitalized for serious or potentially life-threatening exacerbations only, while mild/moderat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::28cd96f45b709ab364c0054b9f9f5dbd
https://doi.org/10.1136/thorax-2020-btsabstracts.28

Zobrazit plný text záznamu

COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels

Autor: Paul Dorinsky, Roopa Trivedi, Patrick Darken, Jadwiga A. Wedzicha, Earl St Rose, Colin Reisner, Chen Wang, Magnus Aurivillius, Shaila Ballal, Dave Singh, Klaus F. Rabe, Gary T. Ferguson, J. McLaren, Fernando J. Martinez

Publikováno v: Airway pharmacology and treatment.

Background: In the 52-week ETHOS trial (NCT02465567), the triple fixed-dose combination BGF MDI containing 320 µg or 160 µg budesonide reduced the rate of moderate/severe COPD exacerbations vs dual therapies. Objective: To assess exacerbation rates

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9d0d65c45bebb1c60808b633c7b865d
https://doi.org/10.1183/13993003.congress-2020.977

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání